Stivarga (regorafenib) — CareFirst (Caremark)

Initial criteria

• Requested for subsequent treatment of unresectable or extrahepatic/metastatic hepatocellular carcinoma as a single agent

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months